Patents by Inventor Douglas G. TILLEY

Douglas G. TILLEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BAG3 AS A TARGET FOR THERAPY OF HEART FAILURE
    Publication number: 20230073246
    Abstract: Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.
    Type: Application
    Filed: October 5, 2022
    Publication date: March 9, 2023
    Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Arthur M. Feldman, Douglas G. Tilley, Weizhong Zhu, Kamel Khalili, Walter J. Koch
  • BAG3 as a target for therapy of heart failure
    Patent number: 11542555
    Abstract: Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: January 3, 2023
    Assignee: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Arthur M. Feldman, Douglas G. Tilley, Weizhong Zhu, Kamel Khalili, Walter J. Koch
  • BAG3 as a target for therapy of heart failure
    Patent number: 11236389
    Abstract: Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: February 1, 2022
    Assignee: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Arthur M. Feldman, Douglas G. Tilley, Weizhong Zhu, Kamel Khalili, Walter J. Koch
  • BAG3 AS A TARGET FOR THERAPY OF HEART FAILURE
    Publication number: 20210017600
    Abstract: Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.
    Type: Application
    Filed: May 21, 2020
    Publication date: January 21, 2021
    Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Arthur M. Feldman, Douglas G. Tilley, Weizhong Zhu, Kamel Khalili, Walter J. Koch
  • TREATMENT OF CARDIOVASCULAR DISEASE WITH COMPOUNDS THAT PROMOTE SELECTIVE INTERACTION OF THE B2-ADRENERGIC RECEPTOR WITH B-ARRESTIN
    Publication number: 20180353567
    Abstract: A pharmaceutical composition and methods of administering the same for treatment of cardiovascular disease comprising a pepducin having a sequence SEQ ID No. 1, wherein said composition stimulates cardiomyocyte contractility and activating the ?2AR/?-arrestin signaling pathway.
    Type: Application
    Filed: October 17, 2016
    Publication date: December 13, 2018
    Applicant: THOMAS JEFFERSON UNIVERSITY
    Inventors: Jeffrey L. Benovic, Richard Carr, III, Douglas G. Tilley
  • BAG3 AS A TARGET FOR THERAPY OF HEART FAILURE
    Publication number: 20170016066
    Abstract: Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.
    Type: Application
    Filed: January 30, 2015
    Publication date: January 19, 2017
    Applicant: Temple University of the Commonwealth System of Higher Education
    Inventors: Arthur M. FELDMAN, Douglas G. TILLEY, Weizhong ZHU, Kamel KHALILI, Walter J. KOCH